APO-THEO ER 400 MG
THEOPHYLLINE : 400 MG · DIN 02358395 · APOTEX INC
Health Canada status: APPROVED
What is APO-THEO ER?
APO-THEO ER 400 MG contains THEOPHYLLINE : 400 MG. It is listed in the Health Canada Drug Product Database under DIN 02358395, held by APOTEX INC, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as approved, status dated 02-Nov-2010. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02358395 |
|---|---|
| Brand name | APO-THEO ER |
| Generic / active ingredient | THEOPHYLLINE : 400 MG |
| Manufacturer | APOTEX INC |
| Strength | 400 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | R03DA04 THEOPHYLLINE |
| AHFS class | 86:16.00 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 02-Nov-2010 |
What can be used instead?
Other Canadian products sharing ATC code R03DA04 THEOPHYLLINE. 6 of 39 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AA-THEO LA | 100 MG | TABLET (EXTENDED-RELEASE) | AA PHARMA INC | MARKETED | DIN 00692689 |
| AA-THEO LA | 200 MG | TABLET (EXTENDED-RELEASE) | AA PHARMA INC | MARKETED | DIN 00692697 |
| AA-THEO LA | 300 MG | TABLET (EXTENDED-RELEASE) | AA PHARMA INC | MARKETED | DIN 00692700 |
| ELIXIR DE THEOPHYLLINE | 80 MG / 15 ML | ELIXIR | LABORATOIRE ATLAS INC | MARKETED | DIN 00627410 |
| THEO ER | 400 MG | TABLET (EXTENDED-RELEASE) | AA PHARMA INC | MARKETED | DIN 02360101 |
| THEO ER | 600 MG | TABLET (EXTENDED-RELEASE) | AA PHARMA INC | MARKETED | DIN 02360128 |
| APO-THEO ER | 600 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | APPROVED | DIN 02358409 |
| PMS-THEOPHYLLINE ELIXIR | 80 MG / 15 ML | ELIXIR | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 00575151 |
| PULMOPHYLLINE ELX | 80 MG / 15 ML | ELIXIR | LABORATOIRE RIVA INC. | DORMANT | DIN 00466409 |
| QUIBRON T SR TAB 300MG | 300 MG | TABLET (EXTENDED-RELEASE) | BRISTOL LABS DIVISION OF BRISTOL-MYERS SQUIBB | CANCELLED POST MARKET | DIN 00556742 |
Who else supplies THEOPHYLLINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. THEOPHYLLINE appears in 1365 registered pack listings across 7 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.